Latest / Pharmacy Podcast Network / Rewriting the Rules: What’s Ahead for Non-PBM Affiliated Specialty Pharmacies | NASP Specialty Pharmacy Podcast
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:09Speaker 1: to the pharmacy profession. Welcome to the Pharmacy Podcast Network.
- 0:26Speaker 2: You're listening to the NASP Specialty Pharmacy Podcast, a collaboration
- 0:31Speaker 2: between the National Association of Specialty Pharmacy and the Pharmacy
- 0:35Speaker 2: Podcast Network. Each episode dives deep into trends, challenges, innovations,
- 0:40Speaker 2: and patient centric practices shaping the future of this dynamic
- 0:44Speaker 2: and rapidly evolving industry. Whether you're a pharmacist or healthcare provider,
- 0:49Speaker 2: patient advocate, or industry leader, you'll hear expert insights, real
- 0:53Speaker 2: world evidence, and thought provoking discussion that highlights all that
- 0:57Speaker 2: makes specialty pharmacy special.
- 1:00Speaker 3: In support of NASP's mission to empower specialty pharmacy stakeholders
- 1:04Speaker 3: to advance the standard of patient care, NASP supports a
- 1:08Speaker 3: free market healthcare system in which all specialty pharmacies compete
- 1:11Speaker 3: on the same fare and level playing field, because that
- 1:14Speaker 3: is in the best interest of the patients we collectively serve.
- 1:17Speaker 3: NASP is committed to working with all stakeholders and policymakers
- 1:21Speaker 3: to ensure that all patients have access to the life
- 1:24Speaker 3: saving medications they need and the high touch patient care
- 1:26Speaker 3: and support services they deserve from the pharmacy of their choosing.
- 1:31Speaker 4: Hello, my name is Sheila Arquette, and I am the
- 1:32Speaker 4: President and CEO of the National Association of Specialty Pharmacy.
- 1:36Speaker 4: I am delighted to welcome two very special guests, Jonathan L.
- 1:40Speaker 4: Swisher and Bradley A. Wasser, to this episode of the
- 1:43Speaker 4: NNASP podcast. Jonathan Swisher is chair of the Dwayne Morris
- 1:47Speaker 4: Pharmacy Litigation Group and a member of the firm's Governing
- 1:51Speaker 4: Partners Board. For more than twenty five years, Mister Swisher
- 1:54Speaker 4: has represented thousands of independent pharmacies and healthcare providers in
- 1:59Speaker 4: regulatories and criminal proceedings. His practice is dedicated to representing
- 2:04Speaker 4: all provider types throughout the United States, including specialty pharmacies,
- 2:08Speaker 4: mail order pharmacies, retail pharmacies, compounding pharmacies, home infusion pharmacies,
- 2:14Speaker 4: telehealth pharmacies, hospital pharmacies, home care pharmacies, long term care pharmacies,
- 2:20Speaker 4: oncology pharmacies, among others. He has handled thousands of matters
- 2:24Speaker 4: on behalf of such providers involving all aspects of their
- 2:27Speaker 4: business operations, including but not limited to issues with payers
- 2:32Speaker 4: and pharmacy benefit managers, PBM audit appeals, challenges to network terminations,
- 2:38Speaker 4: refusals to provide network access, and in the submission of
- 2:42Speaker 4: credentialing applications. Bradley Wasser practices in the area of litigation
- 2:47Speaker 4: with a focus on private antitrust and business counseling and
- 2:50Speaker 4: government efficacy. Mister Wasser has experienced with providing a wide
- 2:54Speaker 4: range of legal, regulatory and business advice for national associations
- 2:58Speaker 4: of healthcare providers, individal vitual healthcare providers and pharmacies, beer wholesalers, retailers,
- 3:04Speaker 4: and high technology firms. Mister Wasser is a member of
- 3:07Speaker 4: Dwayne Morris's Pharmacy Litigation Group. He represents healthcare providers, including pharmacies,
- 3:13Speaker 4: in disputes with insurance companies and pharmacy benefit managers, ranging
- 3:17Speaker 4: from audits to network participation rates, determination of providers from
- 3:22Speaker 4: insurance and pharmacy benefit manager networks. Jonathan and brad thanks
- 3:27Speaker 4: so much for joining me today.
- 3:29Speaker 5: So thanks, thank you Sheila for giving us this opportunity.
- 3:33Speaker 6: Yeah, I was going to say the same thing. It's
- 3:35Speaker 6: great to be with you, Shilla.
- 3:37Speaker 4: So I understand over the past year, state legislatures have
- 3:41Speaker 4: taken the lead in providing greater protections to non PBM
- 3:44Speaker 4: affiliated specialty pharmacies. Give me an overview of the ways
- 3:47Speaker 4: in which states are trying to make things easier for
- 3:50Speaker 4: specialty pharmacies, Sheilla.
- 3:53Speaker 7: It's an excellent question, and I'm sure one that's of
- 3:57Speaker 7: significant importance to many an ESP members. As you noted
- 4:05Speaker 7: in the introduction, I've been doing this for about twenty
- 4:08Speaker 7: five years, and PBMs have been around since the nineteen sixties.
- 4:16Speaker 7: Really wasn't until about five years ago when the US
- 4:22Speaker 7: Supreme Court, in a decision in the case of Rutledge
- 4:27Speaker 7: versus PCMA, took on for the first time in a
- 4:35Speaker 7: fairly public matter an issue as to whether a law
- 4:40Speaker 7: that the state of Arkansas passed to regulate PBMs within
- 4:45Speaker 7: that state was constitutional.
- 4:48Speaker 5: That society in general really began.
- 4:53Speaker 7: To understand who PBMs are, what they do, the extent
- 4:59Speaker 7: to which they influence whether individuals with insurance are able
- 5:06Speaker 7: to receive certain medications, and the extent to which they
- 5:09Speaker 7: influence the ability of pharmacies that are not affiliated with PBMs,
- 5:16Speaker 7: the large chain pharmacies are able to stay in business.
- 5:21Speaker 7: When the US Supreme Court, in the Rutledge case issued
- 5:27Speaker 7: in opinion in order holding that a law that Arkansas
- 5:31Speaker 7: passed requiring that PBMs provide a certain minimum amount of
- 5:38Speaker 7: reimbursement to independent pharmacies in that state. It was really
- 5:45Speaker 7: the first time any authoritative body made clear that pharmacy
- 5:56Speaker 7: benefit managers had in certain instances gone a little too
- 6:01Speaker 7: far with regard to the way in which they were
- 6:05Speaker 7: doing business with pharmacies. They were making it very difficult
- 6:09Speaker 7: for pharmacies to stay in business, and there really was
- 6:15Speaker 7: a need for reform. Almost immediately after the US Supreme
- 6:20Speaker 7: Court held that the Arkansas law, which was called Techno hundred,
- 6:26Speaker 7: was lawful, it gave rise to dozens of other states,
- 6:33Speaker 7: which likely had heard similar complaints over the years from
- 6:38Speaker 7: pharmacies in their states, introducing bills and pretty quickly passing
- 6:45Speaker 7: laws that are analogous of a law at issue in
- 6:50Speaker 7: Arkansas to more aggressively regulate pharmacy benefit managers provide certain
- 6:57Speaker 7: protections to pharmacies, which really for decades they had said,
- 7:02Speaker 7: we're critical to their existence. So over the past year
- 7:08Speaker 7: we probably have seen laws evolving on a state level
- 7:15Speaker 7: at a pace we haven't seen over the past thirty years,
- 7:20Speaker 7: and with regard to the laws that are being passed
- 7:24Speaker 7: on a state level.
- 7:26Speaker 5: Let me just offer up I guess some.
- 7:27Speaker 7: High level observations, and then Brad can follow up with
- 7:34Speaker 7: perhaps some additional specifics.
- 7:36Speaker 5: Now, first, it's important to note.
- 7:39Speaker 7: That dates are able to regulate commercial insurance plans. They
- 7:48Speaker 7: are not able to regulate employer plans. Employer plans are
- 7:56Speaker 7: within the purview of ARISA and arisamps. Any attempts by
- 8:01Speaker 7: the state to regulate insurance. States also do not have
- 8:05Speaker 7: the ability to regulate Medicare plans.
- 8:08Speaker 5: So with regard to commercial insurance, the states.
- 8:13Speaker 7: Have authority to regulate and the main I would say
- 8:19Speaker 7: categories that states have passed laws within the last year
- 8:26Speaker 7: fall into the following categories. First, states are with increasing frequency,
- 8:34Speaker 7: becoming any willing provider states. Any willing provider, as you know,
- 8:39Speaker 7: is a concept that derives from Medicare party. It says
- 8:45Speaker 7: to a PBM or an insurance company that in a
- 8:49Speaker 7: pharmacy is able to comply with fair and reasonable firms
- 8:55Speaker 7: to participate in a network, you have to give them
- 8:59Speaker 7: an opportunity to demonstrate that they can do so. You
- 9:02Speaker 7: can't exclude them from participating from that network if they're
- 9:07Speaker 7: able to satisfy your terms and conditions. So any willing
- 9:11Speaker 7: provider is not only important for Medicare plans. It's obviously
- 9:16Speaker 7: important for the commercial plans that insurance companies have that
- 9:20Speaker 7: are being administered by PBMs. So we've seen additional states
- 9:25Speaker 7: become any willing provider states. We've also seen states that
- 9:31Speaker 7: I would say for years were somewhat reluctant to become
- 9:35Speaker 7: any willing provider states adopt the network adequacy requirements of Medicare.
- 9:44Speaker 7: The network adequacy requirements of Medicare essentially say to insurance
- 9:49Speaker 7: companies and PBMs that if you want to participate in
- 9:57Speaker 7: a particular network, need to ensure that there is a
- 10:02Speaker 7: brick and mortar pharmacy within a certain number of miles
- 10:08Speaker 7: of the insurance plan, the insurance and their members of
- 10:15Speaker 7: the PBM. Otherwise, you need to allow pharmacies within the
- 10:22Speaker 7: requisite mileage participate.
- 10:24Speaker 5: So there are.
- 10:25Speaker 7: Certain states which over the last year have elected not
- 10:29Speaker 7: to become any willing provider states, but instead have stated
- 10:34Speaker 7: that PBMs and insurance companies, if they want to do
- 10:37Speaker 7: business in that state, must agree to comply with the
- 10:41Speaker 7: Medicare network adequacy requirements. And because the mileage that those
- 10:47Speaker 7: requirements say the PBMs and insurance companies must ensure the
- 10:56Speaker 7: insurance will have access to a brick and mortar pharmacy
- 11:02Speaker 7: in terms of the distance from their home. It almost
- 11:05Speaker 7: has converted those states into any bill and provider states
- 11:09Speaker 7: because it can't force individuals any longer as PBMs and
- 11:15Speaker 7: insurance companies have been doing for quite some time to
- 11:18Speaker 7: obtain their medication via mail. They need to obtain medication
- 11:22Speaker 7: really just within a few miles of where they live,
- 11:26Speaker 7: and that's where the independent pharmacies, the pharmacies that are
- 11:29Speaker 7: not the large retail chain pharmacies become relevant.
- 11:36Speaker 5: In addition to network access.
- 11:40Speaker 7: A number of states over the past year have, like Arkansas,
- 11:45Speaker 7: implemented laws with regard to minimum amounts of reimbursement that
- 11:51Speaker 7: PBMs are required to provide to those pharmacies when they've
- 11:55Speaker 7: built medications for their members. A general trend is, at
- 12:03Speaker 7: a minimum, they must reimburse the pharmacies at the NADAK
- 12:08Speaker 7: amount to the extent that a NADAK amount is published.
- 12:13Speaker 7: If a NATEAK amount is not published, then most states
- 12:19Speaker 7: say that we can't reimburse the pharmacy below its wholesale costs.
- 12:23Speaker 7: Far too long, pharmacies have explained about being forced to
- 12:28Speaker 7: accept EBM agreements that would reimburse them below their costs,
- 12:34Speaker 7: thus imposing losses on the pharmacies. And we've seen quite
- 12:37Speaker 7: a few pharmacies now be able to alleviate those problems
- 12:43Speaker 7: because the states have now required reimbursement at a minimum
- 12:48Speaker 7: no less than what their actual costs are. I would
- 12:50Speaker 7: say another category of laws that we've seen over the
- 12:56Speaker 7: last year or so, which is pretty relevant to most
- 13:00Speaker 7: pharmacies is the fact that for quite some time PBMs
- 13:06Speaker 7: would limit the ability of pharmacies to mail medications. They
- 13:12Speaker 7: would either limit the percentage of overall fills that could
- 13:18Speaker 7: be mailed, or they would say that you can't mail
- 13:21Speaker 7: unless you are within a particular PBM male network. Getting
- 13:28Speaker 7: into those networks had for quite some time been very difficult,
- 13:34Speaker 7: required certain accreditations that could be fairly costly for an
- 13:40Speaker 7: independent pharmacy. A number of states within the last year
- 13:45Speaker 7: have made clear recognizing, particularly following COVID when mail to
- 13:51Speaker 7: customers became commonplace, that in this day and age, individuals
- 13:59Speaker 7: are a lot less likely to go to a pharmacy
- 14:03Speaker 7: to get their medications. Pharmacies mailing medications to their customers
- 14:09Speaker 7: is something that can be done properly and safely, and
- 14:13Speaker 7: therefore they pass laws essentially telling PBMs or insurance companies
- 14:18Speaker 7: doing business in that state, you cannot penalize pharmacies for
- 14:24Speaker 7: mailing medications. Therefore, the requirement that pharmacies be admitted into
- 14:34Speaker 7: a mail network if they want to mail, those requirements
- 14:38Speaker 7: are now going by the wayside. Attempts by certain PBMs
- 14:43Speaker 7: or insurance companies to limit the overall percentage of mailings
- 14:48Speaker 7: that a pharmacy would engage in would likewise run a
- 14:52Speaker 7: vowe a particular state law. So pharmacies are now allowed
- 14:59Speaker 7: to mail in a way that up until I would say,
- 15:02Speaker 7: about a year or so ago, they didn't have the
- 15:07Speaker 7: freedom or the ability to do.
- 15:10Speaker 8: So.
- 15:11Speaker 5: Those are just off the top of my head, a
- 15:15Speaker 5: few barely significant reforms.
- 15:18Speaker 7: That we have seen on a state level over the
- 15:22Speaker 7: past year, which or for the pharmacies that are like
- 15:29Speaker 7: were listening to this podcast, really provides substantial benefit. The
- 15:34Speaker 7: only other thing I will say is most of the
- 15:37Speaker 7: forum contracts that are being provided to PBMs or insurance
- 15:42Speaker 7: or by insurance companies to the pharmacies are not taking
- 15:46Speaker 7: into account the somewhat recent changes with regard to state laws,
- 15:53Speaker 7: and therefore, if you are a pharmacy owner or executive,
- 15:59Speaker 7: it truly is imperative that you were reviewing closely the
- 16:03Speaker 7: contract that you were receiving to make sure that that
- 16:07Speaker 7: form contract is taking into account any changes that may
- 16:12Speaker 7: have occurred in your state, because the majority of the
- 16:17Speaker 7: contracts that we are seeing that are being proposed to
- 16:20Speaker 7: pharmacies are not incorporating the way in which the laws
- 16:24Speaker 7: of that state have changed within the past year.
- 16:28Speaker 8: Yeah, and I agree with Jonathan that these are the
- 16:33Speaker 8: highlights coming out of the most recent state legislature, you know,
- 16:39Speaker 8: past bills. You know, one piece that's really interesting and
- 16:44Speaker 8: just to go back into it is the whole.
- 16:46Speaker 6: Mail related iss year.
- 16:48Speaker 8: And I think it's particularly important for you know, the
- 16:51Speaker 8: non affiliated specialty pharmacies who you know, as we all
- 16:56Speaker 8: know you know, who are in this world, often have
- 17:00Speaker 8: access to certain limited distribution drugs that are not carried
- 17:05Speaker 8: by your regular retail pharmacies or your corner pharmacies. So
- 17:10Speaker 8: it's important that specialty pharmacies, particularly non affiliated specialty pharmacies,
- 17:17Speaker 8: have access to be able to deliver medications to those
- 17:20Speaker 8: patients who need medications fill that they can otherwise access
- 17:24Speaker 8: via regular retail channels. So when we see limitations that
- 17:29Speaker 8: PBMs had placed for years on the ability of specialty
- 17:33Speaker 8: pharmacies to mail medications, you know, particularly you know, when
- 17:39Speaker 8: and this is my my cynical nature coming through here,
- 17:43Speaker 8: when a lot of it, you know, Shelle, you might recognize,
- 17:46Speaker 8: you know, I think has been done for particularly competitive reasons,
- 17:50Speaker 8: you know, to give those EBM affiliated uh specialty pharmacies
- 17:55Speaker 8: an advantage to be able to access more customers than
- 17:58Speaker 8: you know, say, the non affiliated specialty of pharmacies maybe.
- 18:01Speaker 6: Able to do. You know.
- 18:03Speaker 8: To me, this is one of the most important revisions
- 18:06Speaker 8: that we're seeing coming out of state laws recently. And
- 18:10Speaker 8: I think, you know, also just to sort of piggyback
- 18:13Speaker 8: on another point that Jonathan raised with respect to certain
- 18:19Speaker 8: reimbursement levels that we're also seeing, you know, from from
- 18:22Speaker 8: our perspective, and.
- 18:24Speaker 6: We can get into this a little bit more.
- 18:27Speaker 8: You know, this is really designed with the goal of
- 18:31Speaker 8: allowing pharmacies to now recoup at least the costs that
- 18:37Speaker 8: they've paid for medications, because, as we know, over the years,
- 18:42Speaker 8: there's been a significant downturn and reimbursement rates that pharmacy
- 18:47Speaker 8: benefit managers have paid to pharmacies, you know, to the
- 18:51Speaker 8: non affiliated pharmacies, you know, and as medications become more expensive,
- 18:58Speaker 8: you know, we see that, you know, there really are
- 19:01Speaker 8: variations and pricing and I think, you know, having.
- 19:04Speaker 6: These you know what they call nay deck the national.
- 19:10Speaker 8: Acquisition costs you know, or wholesale costs being.
- 19:16Speaker 6: Implemented into state.
- 19:17Speaker 8: Law and effectively requiring PBMs to guarantee that minimum reimbursement.
- 19:22Speaker 6: It really will allow independent.
- 19:24Speaker 8: Specialty pharmacies to or not affiliated specialty pharmacies, you know,
- 19:28Speaker 8: to better plan for, you know, the longevity of their businesses,
- 19:33Speaker 8: you know, help take care of their patients, you know,
- 19:36Speaker 8: effectively help plan, you know for for everything that they
- 19:40Speaker 8: can do to to best serve patients in need of
- 19:43Speaker 8: special medications.
- 19:46Speaker 4: So I also understand that there are efforts being made
- 19:49Speaker 4: at the federal level to improve conditions for non PBM
- 19:52Speaker 4: affiliated specialty pharmacies. Let's talk about that a little bit.
- 19:56Speaker 4: Can you provide some examples of what the federal government.
- 19:58Speaker 5: Is doing so on a federal level.
- 20:04Speaker 7: A couple of years ago, the FTC, which you've been
- 20:09Speaker 7: asked by pharmacies for quite some time to study the
- 20:17Speaker 7: way in which EBMs were doing business with them.
- 20:21Speaker 5: Finally, John, I'm.
- 20:23Speaker 6: Gonna interrupt you, just so the pharmacy is listening. No,
- 20:26Speaker 6: and I know everybody's very familiar with this. I just
- 20:29Speaker 6: want to make clear when.
- 20:30Speaker 8: We talk about FTC, we're referring to the Federal Trade Commission,
- 20:34Speaker 8: just so people aren't saying.
- 20:35Speaker 6: Oh, well, what does that acronym. I'm not in Washington,
- 20:39Speaker 6: so I don't understand all the ABC's. I just wanted
- 20:41Speaker 6: to make that clear. So sorry, John, go ahead.
- 20:44Speaker 7: So the FTC finally agreed to move forward with what's
- 20:49Speaker 7: called a six B study. And the purpose of the
- 20:54Speaker 7: six P study, and this occurred during the Biden administration,
- 20:58Speaker 7: was to assess to what extent, if at all, the
- 21:06Speaker 7: three major PBMs were engaged.
- 21:09Speaker 5: In what's called unfair trade practices.
- 21:12Speaker 7: The FTC is tasked by Congress with attempting, among other things,
- 21:17Speaker 7: to identify the extent to which businesses in the US
- 21:22Speaker 7: are involved in unfair trade practices.
- 21:25Speaker 5: Thus the six piece study. They have.
- 21:31Speaker 7: Obtained from the major ppms literally millions of documents over
- 21:39Speaker 7: the past couple of years, which, as we understand it,
- 21:44Speaker 7: they have devoted significant time analyzing to try to assess whether,
- 21:50Speaker 7: in the eyes of the FTC, the major PBMs are
- 21:55Speaker 7: acting unfairly towards independent pharmacies.
- 22:00Speaker 5: Until today, the FTC has.
- 22:03Speaker 7: Already issued two preliminary reports.
- 22:08Speaker 5: Each report is publicly available.
- 22:11Speaker 7: Each report is approximately seventy pages, and over the course
- 22:17Speaker 7: of these two reports, the FTC describes in pretty substantial
- 22:22Speaker 7: detail the various ways in which it believes the evidence
- 22:28Speaker 7: it has already obtained demonstrates that PBMs are and again,
- 22:34Speaker 7: this is the FTC's conclusions acting unfairly towards independent pharmacies.
- 22:41Speaker 5: When the FTC announced.
- 22:44Speaker 7: That it was moving forward with this study, it gave
- 22:48Speaker 7: rise to other federal government agencies deciding that Day two
- 22:55Speaker 7: wanted to investigate the extent to which PBMs may not
- 23:00Speaker 7: be acting fairly towards independent pharmacies. So the House Oversight
- 23:05Speaker 7: Committee announced that it would be conducting almost an identical
- 23:10Speaker 7: investigation to what the FTC was investigating. The House Judiciary
- 23:16Speaker 7: Committee announced that it would be conducting a similar investigation,
- 23:24Speaker 7: and the Department of Justice announced that it was going
- 23:29Speaker 7: to create a Healthcare Task Force, the sole purpose of
- 23:34Speaker 7: which was to itself determine whether or not any of
- 23:40Speaker 7: the conduct of.
- 23:42Speaker 5: PBMs or the insurance companies that.
- 23:45Speaker 7: They work with constitutes a violation of federal law, primarily
- 23:53Speaker 7: the anti trust laws. So within the last year or two,
- 23:59Speaker 7: nearly every every federal agency that is tasked with investigating
- 24:05Speaker 7: and monitoring the healthcare system here in the US has
- 24:10Speaker 7: made it a major initiative to focus on the PBM
- 24:15Speaker 7: pharmacy relationship.
- 24:18Speaker 5: Since the administration has changed, we have.
- 24:22Speaker 7: Not seen any of those agencies led up the investigations
- 24:30Speaker 7: that were put into motion a couple of years ago,
- 24:33Speaker 7: and based upon comments that have been made by representatives
- 24:39Speaker 7: of those agencies, we are anticipating that certain of them
- 24:46Speaker 7: will be issuing final reports by the middle of this year.
- 24:53Speaker 5: When those final.
- 24:54Speaker 7: Reports are issued, it will give rise to some fairly
- 25:01Speaker 7: significant developments on multiple fronts. So, for example, the FTC
- 25:08Speaker 7: has the ability to bring enforcement actions against any entity
- 25:13Speaker 7: it believes is involved in unfair trade practices. If their
- 25:17Speaker 7: final report is consistent with the preliminary reports that they've
- 25:22Speaker 7: already issued, the FTC would then have enforcement authority against
- 25:27Speaker 7: the PBMs that they believe are.
- 25:29Speaker 5: Involved in unfair trade practices.
- 25:33Speaker 7: The FTC would then share that information with the DOJ,
- 25:40Speaker 7: which is made clear that via this Healthcare Task Force,
- 25:43Speaker 7: it's going to move forward with complaints against PBMs.
- 25:50Speaker 5: The information that all of these.
- 25:52Speaker 7: Government agencies have been eliciting also is being closely watched
- 26:00Speaker 7: by members of Congress, and based upon the reports and
- 26:06Speaker 7: other information that these agencies have issued over the last
- 26:10Speaker 7: year or so, some fairly meaningful bills are now being
- 26:16Speaker 7: introduced by partisan bills, which, if they're able to make
- 26:21Speaker 7: their way through Congress, would lead to laws that are
- 26:27Speaker 7: very similar to certain of the laws that I summarized
- 26:31Speaker 7: before on a state level. So on a federal level,
- 26:36Speaker 7: this could be a relatively active year in terms of
- 26:42Speaker 7: investigations and studies starting a couple of years ago. Coming
- 26:46Speaker 7: to a conclusion. I'll pause there and give Brad an
- 26:52Speaker 7: opportunity to jump in and add anything else that he
- 26:55Speaker 7: wants to have contribute.
- 26:58Speaker 8: Yeah, so, I know, I obviously believed that's a great
- 27:00Speaker 8: overview John, you know, as to what's happening on the
- 27:03Speaker 8: federal level. But but interestingly to your point too, you know,
- 27:07Speaker 8: not just Congress. You know that that's watching the actions
- 27:10Speaker 8: that are coming from some of the agencies, But but
- 27:14Speaker 8: and not to go back to the state level too much.
- 27:16Speaker 8: But I think it's also worthy to note that, you know,
- 27:21Speaker 8: at the state level, you know, the various state attorneys
- 27:25Speaker 8: general are also paying close attention to what's coming out
- 27:28Speaker 8: of the federal government, you know, as well as what's
- 27:30Speaker 8: happening in their individual states. You know, we've seen a
- 27:33Speaker 8: number of studies you know, done in Ohio and Michigan,
- 27:37Speaker 8: Pennsylvania over the years also sort of piggybacking on potential
- 27:43Speaker 8: unfair trade practices or unfair methods of competition at the
- 27:47Speaker 8: Federal Trade Commission has been focused on and we've seen
- 27:51Speaker 8: a couple of lawsuits that are now stemming from various
- 27:54Speaker 8: state attorneys general. I think Michigan was the most recent
- 27:59Speaker 8: state to bring a lawsuit concerning various drug pricing practices
- 28:05Speaker 8: in which the pharmacy benefit managers are engaged in. You know,
- 28:09Speaker 8: also coming out of the Federal Trade Commission recently, UH
- 28:14Speaker 8: was a lawsuit that the Federal Trade Commission filed, you know,
- 28:18Speaker 8: during the tendency of its six p study, John, that
- 28:21Speaker 8: you discussed regarding the PBMs UH and you know, their
- 28:28Speaker 8: affiliated purchase excuse me, group purchasing organizations for engaging in
- 28:34Speaker 8: you know, what the FTC deem deemed to be anti
- 28:36Speaker 8: competitive uh and unfair rebating practices that have led to
- 28:41Speaker 8: artificially inflated list price of certain types of medications.
- 28:46Speaker 6: So, you know, I think there's some in terms.
- 28:50Speaker 8: So first of all, you know, the general issues that
- 28:52Speaker 8: the federal government is looking at in terms of you know,
- 28:55Speaker 8: potential competition or you know, or pharmacy benefit managers inhibiting
- 29:00Speaker 8: competition from non affiliated pharmacies, you know, is very interesting
- 29:07Speaker 8: to watch. But I also think there are some particularly
- 29:09Speaker 8: discrete issues like drug pricing issues, et cetera, that that
- 29:13Speaker 8: Congress and certain state attorneys generals are paying close attention to.
- 29:18Speaker 8: H And John and Hill, I'm sure both of you
- 29:20Speaker 8: recently saw out of the most recent House Judiciary Committee hearings.
- 29:27Speaker 8: You know that they followed up to certain PBMs with
- 29:30Speaker 8: requests and you know, regarding practices over what's called uh,
- 29:35Speaker 8: you know, hub pharmacy practices wherein you know, you'll have
- 29:40Speaker 8: a manufacturer who has a specific drug, you know, usually
- 29:43Speaker 8: a limited distribution type drug, you know, often a specialty
- 29:47Speaker 8: drug that they have a select network of pharmacies that
- 29:52Speaker 8: every time they receive a prescription they're able to you know,
- 29:56Speaker 8: have a pharmacy that has access to those drugs filled
- 30:00Speaker 8: medication on behalf of a patient and then ship those
- 30:03Speaker 8: medications out to those patients. For years, certain pharmacy benefit
- 30:07Speaker 8: managers limited the opportunity for pharmacies to participate in those
- 30:12Speaker 8: hubs which you know afforded more access and then do
- 30:15Speaker 8: afford more access to individuals to obtain necessary specialty medications. So,
- 30:21Speaker 8: you know, that's an area that you know Congress is
- 30:23Speaker 8: looking at, particularly the House Judiciary Committee. So I think,
- 30:26Speaker 8: you know, coming out of the federal government's scrutiny over
- 30:30Speaker 8: recent pharmacy benefit manager conduct, is you know, hopefully going
- 30:35Speaker 8: to be beneficial you know, as we move through the
- 30:37Speaker 8: year for the non affiliated specialty pharmacies that we deal
- 30:42Speaker 8: with day in the day out.
- 30:45Speaker 4: So separate from state and federal government action, I understand
- 30:49Speaker 4: the courts have recently been asked to assess whether certain
- 30:53Speaker 4: actions to protect non PBM affiliated specially pharmacies are lawful.
- 30:58Speaker 4: Can you summarize some of those developments.
- 31:00Speaker 5: To shill That's a very timely question.
- 31:06Speaker 7: We mentioned earlier the Ruttledge case, and the Ruttlish case
- 31:10Speaker 7: was the first case in the history of American jurisprudence
- 31:14Speaker 7: to go to the US Supreme Court that involved issues
- 31:18Speaker 7: arising out of the PPM pharmacy relationship.
- 31:23Speaker 5: Now as we speak, there is another.
- 31:27Speaker 7: Case that is at the US Supreme Court level that
- 31:33Speaker 7: potentially could be even more significant for the industry than Rutledge,
- 31:38Speaker 7: and the case arises out of a law that the
- 31:43Speaker 7: state of Oklahoma casked to regulate EBMs. The law that
- 31:49Speaker 7: Oklahoma cass was more expansive than the law.
- 31:54Speaker 5: At issue in Arkansas.
- 31:56Speaker 7: And whereas Arkansas really focused on the permissibility of requiring
- 32:03Speaker 7: more PBMs and insurance companies reimburse pharmacies.
- 32:08Speaker 5: At a minimum level, the y Oklahoma law built.
- 32:14Speaker 7: Much more into the parameters of anyone provider laws.
- 32:20Speaker 5: So they Oklahoma.
- 32:22Speaker 7: Law is dictating to PBMs and insurance companies the circumstances
- 32:29Speaker 7: of which they are required to allow pharmacies to participate
- 32:36Speaker 7: in their networks.
- 32:37Speaker 5: And there are four aspects of that law.
- 32:40Speaker 7: I won't, for purposes of time, go into each category,
- 32:44Speaker 7: but four aspects which the PBMs and PCMA, the lobbying
- 32:52Speaker 7: group that the PBMs work with, have claimed violate Arissa,
- 33:00Speaker 7: as well as certain other laws.
- 33:03Speaker 5: The case when.
- 33:06Speaker 7: It went up to the Federal Court of Appeals held
- 33:11Speaker 7: that the Oklahoma law was unconstitutional because it violated ARISA.
- 33:19Speaker 7: The Attorney General's Office that in Oklahoma filed with the
- 33:25Speaker 7: US Supreme Court a petition for CCIII, asking the US
- 33:32Speaker 7: Supreme Court to consider the appropriateness of the decision rendered
- 33:38Speaker 7: by the Court of Appeals.
- 33:44Speaker 5: Three thing.
- 33:46Speaker 7: Just within the past week has concluded, and there were
- 33:51Speaker 7: some interesting developments in the petition for SARI process that
- 33:55Speaker 7: we do not typically see.
- 33:58Speaker 5: So the US Supreme.
- 34:02Speaker 7: As part of its decision as to whether to hear
- 34:05Speaker 7: the case, asked that the US Solicitor General submit a
- 34:11Speaker 7: brief as to whether it thought that the US Supreme
- 34:16Speaker 7: Court needed to reconsider the Court of Appeal's decision. They're
- 34:22Speaker 7: also was an amicus brief, which is a brief that
- 34:27Speaker 7: is filed by a third party that has an interest
- 34:33Speaker 7: in the matter, that was filed on behalf of a
- 34:36Speaker 7: number of state attorney generals on.
- 34:40Speaker 5: The issues regarding the case.
- 34:45Speaker 7: As of today, when this podcast is being reported, we
- 34:50Speaker 7: understand that the US Supreme Court will be making a
- 34:53Speaker 7: decision within the next couple of weeks as to whether
- 34:57Speaker 7: it will agreed to hear the case. If it does
- 35:01Speaker 7: agree to hear the case, that case could have some
- 35:05Speaker 7: pretty significant ramifications that go beyond the issue as to
- 35:11Speaker 7: whether the Oklahoma law in and of itself is lawful. Again,
- 35:19Speaker 7: what is an issue in Oklahoma is in any willing
- 35:23Speaker 7: provider law, and any willing provider laws have for a
- 35:30Speaker 7: number of years in critical or pharmacies, as those laws,
- 35:40Speaker 7: as I mentioned earlier, require that PBMs and insurance companies
- 35:45Speaker 7: give pharmacies an opportunity to participate in a network. For
- 35:51Speaker 7: pharmacies that are not in states that are any valune
- 35:54Speaker 7: provider laws, there really.
- 35:57Speaker 5: Is nothing prohibiting PBMs.
- 35:59Speaker 7: Or insured as companies from telling those pharmacies when they
- 36:02Speaker 7: want to they want to participate in a particular network
- 36:06Speaker 7: that the networks flows that at that point in time,
- 36:11Speaker 7: they're not looking to add new pharmacies to the network.
- 36:15Speaker 7: So it was really the creation of any willing provider
- 36:21Speaker 7: laws on a state level, again deriving from any willing
- 36:26Speaker 7: provider principles found the medicare part of t that gave
- 36:31Speaker 7: pharmacies the opportunity to participate in commercial plans that they
- 36:37Speaker 7: were being excluded from for a number of years.
- 36:40Speaker 5: So if the US.
- 36:42Speaker 7: Supreme Court agrees to hear them already case, it is
- 36:46Speaker 7: very likely that as part of its analysis as to
- 36:51Speaker 7: whether the Oklahoma any willing provider law is appropriate, it
- 36:57Speaker 7: will delve a little bit deeper in the question as
- 37:00Speaker 7: to whether any willing provider laws a general are appropriate.
- 37:07Speaker 5: Now, without getting too detailed into areas.
- 37:11Speaker 7: Of a law that could be somewhat complicated, the main
- 37:14Speaker 7: issue that exists nationally arises out of laws that do
- 37:22Speaker 7: not specifically exclude either Arissa plans, which again our employee
- 37:27Speaker 7: re sponsored plans.
- 37:29Speaker 5: Or Medicare plans.
- 37:31Speaker 7: The question is to whether or not a state can
- 37:35Speaker 7: regulate Medicare. That's easily answered, a state cannot do that.
- 37:41Speaker 7: As for Arissa, the law becomes a little bit more brave,
- 37:45Speaker 7: and courts of disagree as to whether any willing provide
- 37:50Speaker 7: or laws that would require that a PBM allow a
- 37:54Speaker 7: pharmacy to participate in a network when that network involves
- 37:59Speaker 7: and sponsored plans runs about of Arissa, and therefore the
- 38:07Speaker 7: law would be preempted by Arissa. It belong is preempted
- 38:13Speaker 7: by Arissa. Again, it's not lawful. So, in anticipation of
- 38:18Speaker 7: the us of being cord caring already, some of the
- 38:22Speaker 7: states that I referred to earlier, which over the past
- 38:25Speaker 7: year have expanded their laws to implement any willing provider
- 38:32Speaker 7: principles within their states, have specifically stated when their laws
- 38:37Speaker 7: were passed that their any willing provider laws do not
- 38:41Speaker 7: apply to ARISSA plans, do not apply to Medicare. But
- 38:46Speaker 7: there still are a number of states that have had
- 38:50Speaker 7: any willing provider laws on the books for years that
- 38:53Speaker 7: have not exposedly carved down ARISA or Medicare based plants.
- 39:01Speaker 7: So if the US Supreme Court takes the case, and
- 39:05Speaker 7: if the US Supreme Court were to decide that any
- 39:09Speaker 7: willing provider laws are legally valid so long as they
- 39:13Speaker 7: do not apply to employer sponsored plans, which again discovered
- 39:17Speaker 7: by ARISSA or many PREP plants, it's going to likely
- 39:23Speaker 7: floors a number of states that have not yet specifically
- 39:26Speaker 7: harmed down those types of plans from their any willing
- 39:30Speaker 7: provider laws to amend the laws on the books, and
- 39:35Speaker 7: if they do not proceed to do so, like PCMA,
- 39:39Speaker 7: which is the lobbying in room for their ppms, have
- 39:42Speaker 7: done in Arkansas and with Oklahoma, they will likely precede
- 39:48Speaker 7: the challenge any willing provider laws in other states, which,
- 39:52Speaker 7: again for pharmacies that are not affiliated with the PBMs,
- 39:58Speaker 7: has really been essential to their ability to remain in business.
- 40:05Speaker 5: So the case, if accepted by the US.
- 40:09Speaker 7: Supreme Court, will likely become the most significant judicial matter
- 40:16Speaker 7: to involve the pharmacy industry.
- 40:21Speaker 8: Yeah, and I'll just second what Jonathan said, you know,
- 40:24Speaker 8: and I think you articulated things very well, Jonathan. I mean,
- 40:28Speaker 8: you know, from just a practical standpoint, from these cases
- 40:32Speaker 8: that you know come out of the Supreme Court, I
- 40:36Speaker 8: think states and state legislatures often look to see or
- 40:42Speaker 8: will be at least in the case of Rutledge they did.
- 40:45Speaker 8: And I think whatever comes out of Molready, to the
- 40:48Speaker 8: extent that the Supreme Court ultimately decides to hear the
- 40:51Speaker 8: case or not, is state legislatures paying specific attention to
- 40:56Speaker 8: how they can amend laws to basically fit within the
- 41:00Speaker 8: parameters that the Supreme Court will ultimately come down with.
- 41:06Speaker 6: You know.
- 41:06Speaker 8: So that is an extremely important, I'm already case, an
- 41:11Speaker 8: extremely important case to keep our eyes on, you know,
- 41:14Speaker 8: as we move forward in the next couple of weeks.
- 41:18Speaker 8: But I think we might be remiss too if we
- 41:20Speaker 8: don't just mention and you know, we don't have to
- 41:22Speaker 8: specifically delve into it. Another a pair of lawsuits that
- 41:28Speaker 8: was recently filed at the very end of May, so
- 41:32Speaker 8: they're extremely timely because they also touch.
- 41:37Speaker 6: On certain laws.
- 41:39Speaker 8: Well, one particular law that one state has passed and
- 41:42Speaker 8: that other states are considering, and that is Arkansas's sort
- 41:47Speaker 8: of first of kind law wherein the state decided to
- 41:52Speaker 8: ban PBM ownership of pharmacies within that state. There's been
- 41:59Speaker 8: major your pharmacy benefit managers as a result of that
- 42:03Speaker 8: law that have filed lawsuits arguing that those law, particularly
- 42:10Speaker 8: the Arkansas law, is not constitutional. You know, that violates
- 42:16Speaker 8: certain aspects of the Constitution. And what's interesting is the
- 42:23Speaker 8: theories that are being asserted by the pharmacy benefit managers.
- 42:28Speaker 8: Whereas one major pharmacy benefit manager only talked about constitutional
- 42:33Speaker 8: or potential constitutional violations, whereas another pharmacy benefit manager who
- 42:38Speaker 8: filed a companion lawsuit also has raised in a riscent
- 42:42Speaker 8: issue John, which we know, you know, and as you articulated,
- 42:46Speaker 8: is you know, sort of at the heart of both
- 42:49Speaker 8: the Rutledge case back in twenty twenty and the mole
- 42:52Speaker 8: Ready case that's currently being reviewed. So you know it's
- 42:56Speaker 8: going to be fantastically interesting to see what comes from
- 43:01Speaker 8: these cases and you know whether or not those more
- 43:04Speaker 8: I would say, controversial laws like the law passed in
- 43:08Speaker 8: Arkansas and those that you know some other states are considering,
- 43:13Speaker 8: you know, to see what the courts might say, uh,
- 43:17Speaker 8: you know, as to whether or not those laws you
- 43:19Speaker 8: know will be.
- 43:20Speaker 6: Or or able to be valid on a going forward basis.
- 43:25Speaker 4: So there was a fair amount of anticipation as to
- 43:28Speaker 4: how non PBIUM affiliated specialty pharmacies may benefit or lose
- 43:33Speaker 4: protections once Trump became president, even though he is only
- 43:37Speaker 4: served for less than five months as of this podcast recording,
- 43:42Speaker 4: can you provide some opinions as to whether the change
- 43:44Speaker 4: in administration has helped or hurt specialty pharmacies.
- 43:49Speaker 7: So this was something in early January that in our
- 43:58Speaker 7: practice really was is a frequent topic of discussion. The
- 44:07Speaker 7: fact that on Day one, Trump issued executive orders revoking
- 44:15Speaker 7: executive orders that had previously been issued by President Biden
- 44:21Speaker 7: that appeared to be for the benefit of independent pharmacies
- 44:27Speaker 7: that were focused on lowering drug costs back in January
- 44:34Speaker 7: paused some anxiety among independent pharmacies and their customers as
- 44:43Speaker 7: to whether the initiatives that were put in motion by
- 44:49Speaker 7: President Biden to reduce drug.
- 44:53Speaker 5: Costs, to.
- 44:57Speaker 7: Ensure that the momentum independent farm macies had been benefiting
- 45:03Speaker 7: from with regard to getting into PBM networks, being fairly reimbursed,
- 45:11Speaker 7: et cetera, would continue. But if we look at the
- 45:19Speaker 7: executive orders that have been issued since that mid January timeframe,
- 45:29Speaker 7: we take it face value comments which have been made
- 45:34Speaker 7: by President Trump, members of his administration, members of his family,
- 45:43Speaker 7: and also the comments most recently made with regard to
- 45:47Speaker 7: what President Trump considered to be mandatory requirements with regard
- 45:53Speaker 7: to the pending Big Beautiful Bill. Everything as of today
- 46:01Speaker 7: continues to suggest that the Trump administration is very, very
- 46:08Speaker 7: focused on keeping costs down for medications, but at the
- 46:18Speaker 7: same time ensuring that pharmacies continue to be reimverse fairly
- 46:27Speaker 7: regardless as to how those costs are impacted. So we've
- 46:33Speaker 7: seen nothing among any of the government agencies that I
- 46:38Speaker 7: identify before on a federal level suggesting that they are
- 46:45Speaker 7: reconsidering or deviating from the work that was done by
- 46:52Speaker 7: those agencies before Trump became president. When states are passing
- 47:02Speaker 7: laws that are similar to the laws that I mentioned earlier,
- 47:07Speaker 7: members of those federal government agencies are issuing statements approving
- 47:17Speaker 7: of those laws. And just last night, when a Louisiana.
- 47:22Speaker 5: Law that.
- 47:25Speaker 7: Was anticipated to be passed that would have precluded HEBM
- 47:31Speaker 7: affiliated pharmacies from doing business in Louisiana was struck down,
- 47:42Speaker 7: President Trump's son, Donald Trump Junior, immediately issued a statement
- 47:47Speaker 7: expressing his disappointment that that law was not passed.
- 47:55Speaker 5: So with regard to.
- 48:01Speaker 7: What was considerable momentum over the past couple of years.
- 48:05Speaker 5: On both a federal and state level.
- 48:08Speaker 7: To provide certain protections to independent pharmacies, that momentum has
- 48:17Speaker 7: not appeared to have been disrupted over the last six months.
- 48:22Speaker 7: And while the focus with this administration is primarily going
- 48:28Speaker 7: to be on keeping costs down or individuals with regard
- 48:33Speaker 7: to the drugs that they require, so long as accompanying
- 48:41Speaker 7: that focus is a focus on making sure that whatever
- 48:45Speaker 7: the costs are, the pharmacies that are stocking and dispensing
- 48:50Speaker 7: them are being reimbursed appropriately. As of today, we have
- 48:59Speaker 7: no reason to believe that things will become any less
- 49:04Speaker 7: favorable for independent pharmacies. And I think once we see
- 49:10Speaker 7: the final report from the FTC, final reports or notices
- 49:20Speaker 7: from the House Oversight Committee of the House Judiciary Committee,
- 49:24Speaker 7: and then we see how the DOJ moves forward in
- 49:28Speaker 7: response to all of the evidence that's being gathered by
- 49:33Speaker 7: these government agencies and committees, pharmacies will be able to
- 49:39Speaker 7: be even more confident that the change in the administration
- 49:43Speaker 7: will not disrupt what really has been substantial improvements for
- 49:51Speaker 7: their operations over the past couple of years.
- 49:55Speaker 8: Yeah, and I certainly agree with that assessment, John, You know,
- 50:00Speaker 8: I also think that it's interesting to see that not.
- 50:04Speaker 6: Just interesting, but I think it's fortunate to see that
- 50:07Speaker 6: there is.
- 50:10Speaker 8: I would term it as sharing of goal across administrations,
- 50:15Speaker 8: you know, coming out into the Biden administration into the
- 50:17Speaker 8: Trump administration, uh that there's a desire to see healthcare
- 50:22Speaker 8: prices and drug prices in general decrease. You know, obviously,
- 50:27Speaker 8: with a decrease in cost of drugs, you know, there
- 50:29Speaker 8: could be impact to you know, reimbursements that are provided
- 50:33Speaker 8: to you know, the the pharmacies that are dispensing those medications.
- 50:37Speaker 8: But John, to some of the points that you made,
- 50:40Speaker 8: you know, I think with a focus on price protection
- 50:42Speaker 8: and other protections for pharmacy benefit managers, the goal you know,
- 50:46Speaker 8: through the Trump administration as well as you know, various
- 50:50Speaker 8: actions coming out of the numerous federal agencies that are
- 50:57Speaker 8: looking into this and and actively engaged in space, you know,
- 51:01Speaker 8: are hopefully those those continued protections of pharmacies and and
- 51:06Speaker 8: and because of that, uh, you know, all the studies
- 51:08Speaker 8: that are occurring, you know, the the language that's being
- 51:13Speaker 8: proposed in numerous bills that Congress is looking at, including
- 51:18Speaker 8: the one big beautiful bill or the Reconciliation Bill that
- 51:22Speaker 8: that is now going to be looked at by the Senate.
- 51:25Speaker 6: You know.
- 51:26Speaker 8: All of that's to say that I am glad to
- 51:29Speaker 8: see you know, parody across administrations with the goal of
- 51:33Speaker 8: trying to keep prices down for consumers, yet at the
- 51:36Speaker 8: same time, you know, try to protect the independent specialty
- 51:39Speaker 8: pharmacies or not affiliated pharmacies you know, in in in
- 51:45Speaker 8: the goal of you know, having their longevity protected, uh,
- 51:50Speaker 8: you know, as well as the ability to be able
- 51:53Speaker 8: to be profitable in business and to properly service the
- 51:56Speaker 8: customers that you know are in need of specialty and
- 51:59Speaker 8: other medications.
- 52:02Speaker 4: Well awesome, Thank you so much Jonathan and Brad for
- 52:06Speaker 4: chatting with me and sharing all of this valuable information.
- 52:10Speaker 8: Well thanks shill. It's certainly our pleasure and uh, we're
- 52:13Speaker 8: happy to do this anytime. We can get a weekly
- 52:16Speaker 8: podcast going if you want. There's plenty to talk about
- 52:18Speaker 8: these days, is you know, like we said, bills are
- 52:22Speaker 8: not just bills, but you know, things are coming out
- 52:25Speaker 8: at a weekly clip, so it's it's often hard to
- 52:28Speaker 8: keep up with the pace.
- 52:30Speaker 5: Thank you, sheille give me appreciate the off.
- 52:32Speaker 4: To me of course. Of course, as a reminder, n
- 52:36Speaker 4: SP corporate members are invited to be my guest on
- 52:39Speaker 4: one complimentary podcast per year. For more information about this
- 52:42Speaker 4: or other n SP membership benefits and events, please feel
- 52:46Speaker 4: free to reach out to membership at n A, s P,
- 52:49Speaker 4: n E T dot org or visit our website www
- 52:53Speaker 4: dot n E, s P and E T dot org.
- 52:56Speaker 4: Until next time, have a great day.